Beijing Sciecure Pharmaceutical Co., Ltd.

BEIJING, March 10, 2026 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. ("Tsingke Biotech") and iGeneTech Bioscience Co., Ltd. ("iGeneTech") have announced a strategic partnership aimed at advancing the field of synthetic biology. This collaboration brings together the strengths of both companies to drive innovation, streamline product development, and expand market reach. Harnessing Expertise to Transform the Industry Continue Reading The partnership was formalized at a signing ceremony held at Tsingke Biotech’s Beijing headquarter, where both companies expressed their shared commitment to revolutionizing synthetic biology in response to the growing needs of the market. Synthetic biology is rapidly emerging as a transformative field with wide-reaching applications, including precision medicine, bio-breeding, and gene editing. At the core of these advancements are high-throughput and column-based synthesis, which Tsingke Biotech and iGeneTech aim to further develop. Tsingke Biotech, a leader in gene synthesis, has developed a fully integrated industrial chain that spans raw materials, equipment, process design, AI, and digital technologies. Known for its scalability, standardization, and stability, the company's cutting-edge technology includes column synthesis and an intelligent factory-driven production system that supports from small-scale laboratory production (2nmol) to large-scale industrial synthesis (12mmol). Their gene synthesis services include: Primer Synthesis (<300nt) Gene Synthesis (300bp–5kb) Long Gene Synthesis (>5kb) On the other hand, iGeneTech contributes its proprietary Ignite 3.0 high-throughput synthesis platform. With its ability to process oligo pools ranging from 4k to 650k in size and achieve synthesis lengths up to 200nt with error rates as low as 0.2%, this platform addresses key challenges around throughput, speed, and cost. A Shared Vision for Growth "We are excited to partner with iGeneTech, whose expertise in gene capture and next-generation sequencing (NGS) technology enhances our strengths in gene synthesis," said Mr. Shijin Ma, CEO of Tsingke Biotech. "This partnership will speed up the translation of technological innovations into real-world applications, helping drive the industry forward." Mr. Wanshi Cai, CEO of iGeneTech, added, "Tsingke Biotech's integrated industrial chain and leadership in gene synthesis will be crucial in supporting our continued growth. Together, we will push the boundaries of synthetic biology and its potential across various industries." Both companies are committed to developing an integrated system that spans the entire spectrum from "synthesis" to "application," focusing on innovation, sustainability, and precision to meet the needs of a rapidly evolving market. About Tsingke Biotech Tsingke Biotech is a leading innovator in synthetic biology, with a mission to build "the world's great gene factory." Combining proprietary reagents, consumables, and synthesis equipment with AI-driven molecular manufacturing technologies, Tsingke Biotech provides efficient and high-quality gene synthesis services. Its work supports industries ranging from biopharma to agriculture, food, and environmental sciences. About iGeneTech iGeneTech specializes in gene capture technologies and holds intellectual property in NGS probe hybridization, multiplex PCR, and high-throughput DNA synthesis. The company's high-quality oligo pool synthesis capabilities enable the creation of precise and uniform sgRNA libraries for gene-editing applications, including genome-wide and target-gene sgRNA libraries, and off-target detection. Contact: [email protected] SOURCE Beijing Tsingke Biotech Co., Ltd. 21% more press release views with Request a Demo

From January 12th to 15th, Pacific Time, the 44th J.P. Morgan Healthcare Conference was grandly held in San Francisco, USA. As a "bellwether" in the global biopharmaceutical field, this conference brought together top pharmaceutical companies, investment institutions, and industry elites from the world. Beijing Sungen Biomedical Technology Co., Ltd. (hereinafter referred to as "Sungen Biomedical"), a strategically controlled subsidiary of Hotgen Biotech, made a striking appearance at the conference with its next-generation cornerstone drug for tumor immunotherapy, SGT003. Through presentations and demonstrations, the company fully showcased its innovative capabilities and clinical application potentials, attracting significant attention from international capital markets and industry peers. Tumor treatment has gone through iterations of chemotherapy and targeted therapy, and is now entering an innovative stage focusing on immunotherapy. However, traditional single-target immune checkpoint inhibitors (such as PD-1/PD-L1 monoclonal antibodies) still face problems such as limited response rates and drug resistance. Bispecific antibodies, through their unique mechanism of "simultaneously targeting two targets and acting synergistically," are ushering in the era of "immunotherapy 2.0." Market data showed that the global market size for bispecific antibody drugs for cancer treatment was approximately US$13 billion in 2024, and is expected to exceed US$17 billion in 2025, projected to surge to US$26.8 billion in 2026, maintaining a consistently high compound annual growth rate. However, as of the end of 2024, only 16 bispecific antibody drugs for cancer treatment had been globally approved, and the targeted antigens are relatively limited, far from meeting clinical needs. As a crucial target in immunotherapy, CTLA4 possesses an irreplaceable core advantage in activating anti-tumor immune responses – it removes inhibition during the initiation phase of immune responses, activates the proliferation and differentiation of naive T cells, and builds a strong immune foundation for subsequent tumor killing. It is one of the key targets for achieving long-term anti-tumor efficacy. Sungen Biomedical deeply cultivates into research of tumor immune mechanisms, accurately grasping industry pain points and the core value of the CTLA4 target. They have innovatively built a dual-target drug development platform focusing on CTLA4 and have established a series of bispecific antibody product pipelines. SGT003 is one of these promising potential First-in-Class candidate drugs. The core innovation of SGT003 lies in its dual mechanisms of action: "precisely eliminating tumor microenvironment Tregs + activating anti-tumor immunity." In preclinical studies, it demonstrated excellent tumor-specific killing effects, not only precisely targeting on tumor tissue but also regulating the tumor microenvironment and trigering the body's own immune responses. This significantly reduces the immune activation - related toxic effects of currently marketed CTLA4 antibodies and effectively covers a broad range of solid tumor patients resistant or unresponsive to traditional treatments. Compared to similar drugs, SGT003 shows significant advantages in target affinity, tissue penetration and safety, providing a new treatment option for cancer patients. Currently, SGT003 has completed preclinical development and been planned for dual IND filing in the US and China in 2026. As a cornerstone therapy of the new generation, SGT003's unique design and global development vision fully demonstrate the breakthroughs of Chinese pharmaceuticals in the field of original innovation, laying a solid foundation for global R&D and commercialization of SGT003. In the future, Sungen Biomedical will continue to advance the clinical translation and global deployment of SGT003, breaking down industry barriers through original innovation and helping Chinese innovative drugs gain a core position in the global oncology immunotherapy market.

The approach aims to implement a risk-sharing model, optimise capital allocation and improve efficiency to preserve project value. Credit: PanuShot/Shutterstock.com. Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for a total consideration of 200m yuan ($28m). The move is part of Jacobio Pharma’s subsidiary Beijing Jacobio Pharmaceuticals’ capital increase and equity transfer agreement signed with Oceanpine Capital and an industry partner. The deal value is an upfront payment of 125m yuan, with an additional 75m yuan to be paid as a milestone payment in a second instalment. Upon completion, Oceanpine Capital will hold an 80% stake in Jacoray, while the industry partner and Beijing Jacobio will each own 10%. Jacoray serves as the project company for Jacobio’s cardiovascular research programme, currently in its early stages. This transaction is in line with Jacobio’s focus on advancing oncology therapies such as iADC and Kirsten rat sarcoma viral oncogene homolog (KRAS). GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The approach aims to implement a risk-sharing model, optimise capital allocation, and improve operational efficiency to preserve long-term project value. The transaction’s proceeds will predominantly be allocated to research and development, production and the commercialisation of Jacobio’s Pan-KRAS inhibitor and other oncology assets. Oceanpine Capital founder, CEO and managing partner Dave Chenn stated: “Jacobio demonstrates outstanding scientific strength and strategic focus in oncology innovation. Oceanpine Capital looks forward to partnering with Jacobio to advance the globalisation of China’s biotech innovation.” Jacobio chairman Dr Yinxiang Wang stated: “This partnership with Oceanpine Capital strengthens our strategic focus on oncology innovation and reinforces our commitment to advancing next-generation cancer therapies.” In October 2024, Jacobio Pharma’s internally developed KRAS glycine-to-cysteine mutation at codon 12 (G12C) inhibitor, glecirasib, received orphan drug designation from the European Medicines Agency. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now